MeiraGTx Limited Company Profile

17:34 EDT 19th April 2018 | BioPortfolio

News Articles [35 Associated News Articles listed on BioPortfolio]

Oxford Genetics Forms Adeno-associated Virus Collaboration with MeiraGTx

MeiraGTx gets research and manufacturing rights to novel serotype specific AAV vectors

MeiraGTx obtains rare disease designation for gene therapy A001

Gene therapies developer MeiraGTx has obtained rare paediatric disease designation from the US Food and Drug Administration (FDA) for its...Read More... The post MeiraGTx obtains rare disease designat...

Oxford Genetics announces adeno-associated virus collaboration with MeiraGTx

Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, has established a new agreement with clinical-stage gene therapy company...

Oxford Genetics and MeiraGTx collaborate on AAV vectors

UK-based synthetic biology company, Oxford Genetics, has established a new agreement with clinical-stage gene therapy company, MeiraGTx, for the development of novel adeno-associated virus (AAV) vecto...

Oxford and MeiraGTx to make AAVs in Central London, UK

Oxford Genetics has teamed with MeiraGTx to develop GMP-grade AAVs at a manufacturing facility in Central London, UK.

MeiraGTx’s Leber’s Congenital Amaurosis Drug Receives Rare Pediatric Disease Designation from the FDA

LONDON and NEW YORK, Dec. 7, 2017 /PRNewswire/ — MeiraGTx, a London and New York-based gene therapy company, today announced that the Offices of Orphan Products Development and Pediatric Therape...

MeiraGTx Announces Confidential Submission of Draft Registration Statement for Initial Public Offering

MeiraGTx Limited today announced that it has confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission (the “SEC”) rel...

MeiraGTx Earns EMA PRIME Designation for Achromatopsia Gene Therapy Candidate

A new gene therapy to treat a debilitating eye disorder is one step closer to regulatory approval in Europe.

PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [83 Associated Companies listed on BioPortfolio]


MeiraGTx is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company is developing pote...

MeiraGTx Limited

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...


More Information about "MeiraGTx Limited" on BioPortfolio

We have published hundreds of MeiraGTx Limited news stories on BioPortfolio along with dozens of MeiraGTx Limited Clinical Trials and PubMed Articles about MeiraGTx Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MeiraGTx Limited Companies in our database. You can also find out about relevant MeiraGTx Limited Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record